Brian Skorney
Stock Analyst at Baird
(3.29)
# 932
Out of 4,829 analysts
108
Total ratings
41.33%
Success rate
4.07%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Outperform | $102 → $105 | $76.76 | +36.79% | 4 | May 8, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $118.17 | +115.79% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $527.78 | +11.22% | 15 | Apr 30, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $57 | $20.24 | +181.62% | 3 | Apr 28, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $44.27 | +24.24% | 5 | Feb 27, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $46 | $11.41 | +303.16% | 1 | Dec 13, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $13.63 | +120.10% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.40 | +1,150.94% | 4 | Nov 29, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $26 → $20 | $5.27 | +279.51% | 6 | Nov 26, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $200 → $193 | $36.27 | +432.12% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $95 | $96.91 | -1.97% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.03 | +397.02% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $2.22 | +350.45% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $265.86 | -19.13% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $115.71 | +55.56% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $2.69 | +940.89% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $30.68 | +102.09% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $7.52 | +418.62% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $35.02 | +79.90% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $424.99 | -23.53% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $14.02 | -28.67% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.26 | +11,846.90% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.17 | +89.27% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.89 | +15,773.02% | 3 | May 7, 2018 |
Soleno Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $102 → $105
Current: $76.76
Upside: +36.79%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $118.17
Upside: +115.79%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $527.78
Upside: +11.22%
Biohaven
Apr 28, 2025
Maintains: Outperform
Price Target: $60 → $57
Current: $20.24
Upside: +181.62%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $44.27
Upside: +24.24%
Dyne Therapeutics
Dec 13, 2024
Initiates: Outperform
Price Target: $46
Current: $11.41
Upside: +303.16%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.63
Upside: +120.10%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.40
Upside: +1,150.94%
Enanta Pharmaceuticals
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $5.27
Upside: +279.51%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $200 → $193
Current: $36.27
Upside: +432.12%
Nov 7, 2024
Maintains: Neutral
Price Target: $80 → $95
Current: $96.91
Upside: -1.97%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $5.03
Upside: +397.02%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $2.22
Upside: +350.45%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $265.86
Upside: -19.13%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $115.71
Upside: +55.56%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $2.69
Upside: +940.89%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $30.68
Upside: +102.09%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $7.52
Upside: +418.62%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $35.02
Upside: +79.90%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $424.99
Upside: -23.53%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $14.02
Upside: -28.67%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.26
Upside: +11,846.90%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.17
Upside: +89.27%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.89
Upside: +15,773.02%